Filtry
The clinical significance of angiogenic markers in patients with renal cell carcinoma (NR8914)
To verify the soluble and membrane associated angiogenic factors reflected the growth activity of renal cell carcinoma and set up there prognostic value. To pick out some parameters (VEGF, bFGF, TGF, CD105) to determine the...
FN - Epidemiologie, infekční nemoci a klinická imunologie
- 2006 - 2009 •
- 3 619 tis. Kč •
- 3 616 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2006 - 31. 12. 2009
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Anti-tumour therapy - vaccination with dendritic cells in patients with metastatic renal cell carcinoma. Phase II clinical study. (NT11137)
Prognosis of patients with metastatic renal cell carcinoma is poor with median cell carcinoma but open this combination approach to various cancer types. on interleukin-12 producing autologous dendritic
FD - Onkologie a hematologie
- 2010 - 2013 •
- 5 619 tis. Kč •
- 5 619 tis. Kč •
- MZ
Řešení projektu: 1. 9. 2010 - 31. 10. 2013
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Etiopathogenetic role and prognostic significance of PAX 2 and PAX 8 expression and microsatelite instability on chromosome 3 and 9 in renal cell carcinoma (NC7519)
The goal of the study is to evaluate tho pathogenetic and prognostic role of expression of genes PAX 2 and PAX 8 and microsatellite on chromosomes 3 and 9 in renal cell carcinoma tissue. Results will be correlated with the ...
FD - Onkologie a hematologie
- 2003 - 2005 •
- 2 185 tis. Kč •
- 2 185 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2003 - 1. 1. 2005
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Identification of novel biomarkers panels in selected malignancies (FR-TI3/666)
, renal clear cell carcinoma, pancreatic cancer and colorectal cancer ). We...
FD - Onkologie a hematologie
- 2011 - 2014 •
- 26 530 tis. Kč •
- 20 138 tis. Kč •
- MPO
Řešení projektu: 1. 4. 2011 - 30. 9. 2014
Uznané náklady
Podpora ze státního rozpočtu (76%)
Poskytovatel: Ministerstvo průmyslu a obchodu
Identification of new prognostic markers and update on staging of locally advanced renal cell carcinoma by microRNA expression profiles analysis (NS10361)
Prognostic miRNAs, identified by analysis of miRNAs expression profiles obtained by use of Real-Time PCR miRNA Arrays or their targets on the protein level, enable identification of patients with LARC at high risk of disease progression and individua...
FD - Onkologie a hematologie
- 2009 - 2011 •
- 4 174 tis. Kč •
- 3 988 tis. Kč •
- MZ
Řešení projektu: 1. 1. 2009 - 31. 12. 2011
Uznané náklady
Podpora ze státního rozpočtu (96%)
Poskytovatel: Ministerstvo zdravotnictví
Mitochondrial respiratory complex II aberrations as complication in renal cancer therapy based on mitochondrial targeting (NU23-03-00226)
with promising mitochondrial targeted anti-cancer drug MitoTam, which revealed that clear cell renal cell carcinomas (ccRCC) are particularly susceptible to treatment of renal cancer cell
Biochemistry and molecular biology
- 2023 - 2026 •
- 12 546 tis. Kč •
- 12 546 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2023 - 31. 12. 2026
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Study od epithelial-to-mesenchymal transition associated microRNAs and genes as potential markers for prediction of risk and early detection of metastatic disease in renal cell carcinoma patients (NT13547)
The EMT status reflecting miRNAs identified by expression profiling analysis using Real-Time PCR miRNA Arrays or their target molecules on protein level will enable to identify RCC patients with increased risk of metastatic disease, and by that will ...
FD - Onkologie a hematologie
- 2012 - 2015 •
- 7 431 tis. Kč •
- 7 431 tis. Kč •
- MZ
Řešení projektu: 1. 4. 2012 - 31. 12. 2015
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Integration of multi-omics and bioinformatics tools for renal cell carcinoma recurrence risk prediction and adjuvant cancer treatment personalization (NW25-03-00122)
Renal cell carcinoma (RCC) represents approximately 2-3% of all cancers and the Czech Republic has long been among the countries with the highest incidence of these malignancies. Radical surgery is the mainstay of treatment...
Oncology
- 2025 - 2028 •
- 13 435 tis. Kč •
- 13 435 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2025 - 31. 12. 2028
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Proteotype classification of renal cell carcinoma for prognosis and therapy response (NV19-08-00250)
Renal cell carcinoma (RCC) represents a serious oncological disease with the highest incidence in the Czech Republic across the world, for which reliable molecular prognostic and predictive biomarkers are still unavailable....
Oncology
- 2019 - 2023 •
- 9 221 tis. Kč •
- 9 221 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2019 - 31. 12. 2023
Uznané náklady
Podpora ze státního rozpočtu (100%)
Poskytovatel: Ministerstvo zdravotnictví
Prognostic and predictive molecular factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (NV15-34678A)
The main cause of morbidity and mortality of patients with renal cell carcinoma is the progression to metastatic disease (mRCC). Identification and validation of biomarkers has the potential to improve the therapeutic resul...
FD - Onkologie a hematologie
- 2015 - 2018 •
- 9 007 tis. Kč •
- 8 747 tis. Kč •
- MZ
Řešení projektu: 1. 5. 2015 - 31. 12. 2018
Uznané náklady
Podpora ze státního rozpočtu (97%)
Poskytovatel: Ministerstvo zdravotnictví
- 1 - 10 z 5 575